NBIX 📈 Neurocrine Biosciences - Overview

Neurocrine Biosciences Inc is a pharmaceutical company that focuses on developing treatments for a range of neurological, neuroendocrine, and neuropsychiatric disorders. The company's product portfolio includes INGREZZA, which is used to treat tardive dyskinesia and chorea associated with Huntington's disease, as well as ALKINDI for adrenal insufficiency. Additionally, they offer Efmody capsules for classic congenital adrenal hyperplasia, Orilissa tablets for endometriosis, and Oriahnn capsules for uterine fibroids. These products have been developed to address specific medical needs, and the company continues to expand its portfolio through research and development.

The company's pipeline includes several product candidates in clinical development, such as valbenazine for treating dyskinetic cerebral palsy in pediatrics and adults, and NBI-921352 for developmental and epileptic encephalopathy syndrome. They are also working on NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep, and NBI-1076986 for movement disorders. Furthermore, the company is developing crinecerfront to treat congenital adrenal hyperplasia in adults and children, and EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults. These product candidates are at various stages of clinical development, and the company is working to bring them to market to address unmet medical needs.

Neurocrine Biosciences has established partnerships with several other pharmaceutical companies, including Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, and Idorsia Pharmaceuticals Ltd. These collaborations enable the company to leverage the expertise and resources of its partners to develop new treatments. The company has also partnered with Xenon Pharmaceuticals Inc, Voyager Therapeutics, Inc, BIAL - Portela & Ca, S.A, Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. These partnerships are a key part of the company's strategy to develop and commercialize new products.

Founded in 1992, Neurocrine Biosciences is headquartered in San Diego, California, and is listed on the NASDAQ stock exchange under the ticker symbol NBIX. The company's common stock is classified under the GICS Sub Industry: Biotechnology, and its ISIN is US64125C1099. With a strong focus on research and development, Neurocrine Biosciences is committed to developing innovative treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company's website, https://www.neurocrine.com, provides more information on its products, pipeline, and partnerships.